reported that the upregulated expression of IRF7 in doxorubicin- and methotrexate-treated tumor cells could induce a switching from the myeloid-derived suppressor cell-mediated immune responses to the CD4+/CD8+ T cell-dependent anticancer responses through constitutive activation of type I IFN pathway (22). Here, CD4 is linked to neoplasm.